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ABSTRACT 
While physiological levels of glucocorticoids are required to ensure proper functions of the 
body, consistently high levels may engender several deleterious consequences. We have 
previously shown an increase in the activity of the hypothalamic-pituitary-adrenal (HPA) axis 
in rats fed sucrose rich diets (SRD). The main goal of this study was to analyze the processes 
involved in the modulation of the pituitary production of ACTH by SRD, and to test 
melatonin as a possible therapeutic agent for the prevention of the HPA axis dysfunction. 
Male Wistar rats were fed standard chow and either SRD (30% sucrose in the drinking water) 
or plain water for three weeks. Melatonin was administered as subcutaneous pellets. Results 
showed that SRD treatment induced an increase in systemic ACTH and corticosterone levels 
and a decrease in melatonin levels. In the pituitary gland, we also detected an increase in the 
expression levels of proopiomelanocortin (POMC) that was accompanied by increased levels 
of: lipoperoxides, nitro-tyrosine modified proteins, catalase, heme oxygenase-1, interleukin-
1β mRNA, and by an increase in the tissue number of inflammatory cells (F4/80 and Iba-1 
positive cells). Melatonin treatment prevented all these systemic and pituitary changes as well 
as the increase in POMC expression induced by incubation of AtT-20 corticotrophs with 
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conditioned media obtained from stimulated macrophages. In conclusion, stimulation of 
POMC/ACTH production in rats fed a SRD could involve the generation of oxidative stress 
and inflammation in the pituitary gland. Melatonin treatment prevented these effects and 
normalized the activity of the HPA axis.   
 
INTRODUCTION 
Glucocorticoids (GCs) exert essential roles on several aspects of normal cellular and 
physiological processes. In addition to their effects on glucose metabolism, GCs affect cell 
survival, proliferation, reproduction, growth, cognition, and behavior, also exerting regulatory 
effects on the cardiovascular, the immune, and the central nervous systems
1,2
. GCs, final 
effectors in the stress response, are synthesized and released by the adrenal cortex after 
binding of pituitary ACTH to specific melanocortin-2 receptors and activation of a 
downstream signaling pathway. ACTH is, in turn, a proteolytic processing product of the 
prohormone proopiomelanocortin (POMC), whose synthesis is induced by the hypothalamic 
peptides corticotropin-releasing hormone (CRH) and arginine-vasopressin, upon activation of 
upper levels of the central nervous system. 
 
Sustained excessive GC levels, as those present in patients with Cushing’s syndrome, are 
associated with an increase in morbidity and mortality due to cardiovascular, thrombotic, 
metabolic, infectious and musculoskeletal complications
3-5
. Hypercortisolism has been 
ascribed in many of these patients to increased ACTH production by pituitary ACTH-
secreting tumors
6,7
. Patients with hypercortisolism present with many of the characteristics of 
the metabolic syndrome, among them, visceral fat deposition, hyperglycemia, higher levels of 
plasma non-esterified free fatty acids, obesity and insulin resistance (IR)
8-11
. In fact, a role for 
GCs in the development and maintenance of obesity and IR syndrome has been 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
suggested
12,13
. Recently, we have demonstrated that the administration of a sucrose rich diet 
to Wistar rats (30% sucrose in the drinking water, SRD) stimulates the activity of the 
hypothalamic-pituitary-adrenal (HPA) axis and induces insulin resistance (IR) after 7 weeks 
of treatment
14
. 
 
Processing a high metabolic load, as in rats fed SRD, involves the generation of oxidative 
stress and inflammation as reported in adipose tissue and liver
15,16
. Moreover, the activity of 
the HPA axis has been shown to be modulated by reactive oxygen species (ROS) and 
cytokines
17-23
. In particular, increased ACTH production by pituitary corticotroph cells 
incubated with cytokines
24
 or supraphysiological glucose concentrations through a ROS-
dependent mechanism has been demonstrated 
25
. 
 
Melatonin (5 methoxy-N-acetyltryptamine), the hormone mainly produced by the pineal 
gland is a multitasking molecule involved in multiple aspects of the physiological regulation 
of body functions such as circadian rhythms, immune responsiveness and reproductive 
activity in seasonally reproductive animals
26-29
. A large body of evidence indicates that 
melatonin is also a major scavenger of oxygen- and nitrogen-based reactive molecules at both 
physiologic and pharmacologic concentration
30,31
. Moreover, several intracellular enzymatic 
antioxidant enzymes, including superoxide dismutase, and glutathione peroxidase, among 
others, are stimulated by melatonin
32-34
. In addition to these many antioxidant properties, 
different lines of evidence demonstrate melatonin anti-inflammatory properties, such as a 
decrease in cytokine production and nitric oxide synthase-2 inhibition
35,36
. In the present 
study, we analyzed the effect of SRD on the HPA axis activity at early stages of treatment 
(i.e., before the occurrence of IR). Moreover, since oxidant and inflammatory mechanisms 
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could be involved in the effects of SRD on the synthesis and release of ACTH at pituitary 
level, we analyzed whether melatonin is able to abate HPA axis alterations.  
 
2. Materials and Methods 
2.1 Animals 
Adult male Wistar rats (200-250g) were housed in groups (3 animals / cage) and maintained 
under controlled conditions of humidity and temperature (21±2°C) under a 12h light-dark 
cycle. Rats were fed a standard chow diet ad libitum and either tap water (Control group) or 
30% sucrose in tap water (30% w/v, SRD groups). All protocols were approved by the 
Animal Care and Use Committee (CICUAL) from Facultad de Medicina, Universidad de 
Buenos Aires and followed the “Principles of laboratory animal care” (NIH publication no. 
85-23, revised 1985).   
 
2.2 Melatonin treatment 
At the beginning of the experimental period indicated groups were implanted with a 
subcutaneous pellet of melatonin (20 mg with 3% w/v vegetable oil, compressed in a cylinder 
of 2.5 mm diameter and 1 mm length), while other groups were sham-operated without pellet 
implantation. The pellet of melatonin was implanted subcutaneously under the skin of the 
neck, and was replaced at mid-treatment
37
. Melatonin was obtained from Sigma Chemical Co. 
(St Louis, MO, USA). 
 
2.3 Tissue and serum samples 
Animals were sacrificed by decapitation, between 9 a.m. and 10 a.m., in order to minimize 
circadian variation among groups and trunk blood was collected. Anterior pituitary glands 
were dissected on ice and tissues were homogenized in 50 mmol/L Na2HPO4 pH 7.4, 0.2 
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mmol/L EDTA, 100 mmol/L KCl, 1X protease inhibitor cocktail (Sigma Aldrich, Argentina), 
or in TRI® reagent (Genbiotech, Argentina) for total RNA isolation. 
 
2.4 Biochemical and hormonal measurements  
Corticosterone levels were determined in serum samples by RIA after dichloromethane 
extraction, as described previously
38
. Plasma ACTH concentration was determined using 
Immulite 2000
® 
(Siemens, Germany), and fasting serum glucose, triglyceride and NEFA 
levels were assessed by colorimetric commercial assays (Wiener Lab, Argentina and Randox, 
County Antrim, UK, respectively). Serum melatonin levels were analyzed via a competitive 
ELISA (IBL International Inc., Germany) according to the manufacturer’s instructions. Blood 
samples for this assay were collected from the tail vein at zeitgeber time 18 (ZT18, 2 am). 
 
2.5 Oxidative stress parameters and antioxidant enzymes 
Pituitary tissues obtained from each animal were homogenized in 400 µl 15 mM 
KH2PO4/K2PO4, 60 mM KCl pH 7.4 added with 1X protease inhibitors. Homogenates were 
centrifuged for 10 min at 1000 x g at 4ºC and supernatants were used. Lipid peroxide levels  
were determined as thiobarbituric acid reactive species (TBARS) as previously described
39
.  
 
Catalase activity was determined according to published procedures
40
 with minor 
modifications. Briefly, pituitary homogenates were diluted 1:10 in 50 mM sodium phosphate 
buffer pH 7.4 and 100 µl of this dilution were placed in a spectrophotometric cuvette. 
Reactions were initiated by the addition of 60 µl of 2.5 Vol H2O2 (223 mM) and the 
absorbance at 240 nm was monitored for 120 seconds. Activity, expressed as µM of H2O2 
consumed per min per mg protein, was calculated from the slope of the corresponding curve, 
considering a molar absorptivity of 0.0394 mM
-1
cm
-1
 for H2O2.   
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2.6 Immunohistochemistry 
Animals were anesthetized with a ketamine and xylazine cocktail (50 mg/kg and 2 mg/kg 
respectively) and intracardially perfused with 4% paraformaldehyde in 0.1 M sodium 
phosphate buffer pH 7.4. Pituitary tissues were dissected, post-fixed in the same fixative for 
12 h and dehydrated by incubating with solutions of increasing ethanol concentration (70%, 
90% and 100% v/v). Tissues were clarified with N-butyl acetate and embedded in paraffin 
(Biopack, Argentina). Pituitary glands were serially sliced in 4 µm sections using a rotating 
microtome (RM2125 RTS, Leica, Germany) with every section collected on charged slides 
and then dehydrated by heat (50ºC for 10 min). After deparaffinization and rehydration, 
antigen retrieval was performed by incubating the sections in citrate buffer (10 mM sodium 
citrate, 0.05% Tween-20 pH 6.3) for 30 min at 100ºC. Tissue permeabilization was induced 
by incubating the sections with 0.3% Triton X-100 in 1X PBS. After three washes with 1X 
PBS sections were incubated for 1 h in a blocking solution (2% normal horse serum). 
Immunodetection was performed with rabbit anti-ACTH (1:1000, Santa Cruz Biotechnology 
Cat# sc-52980, RRID: AB_831670) or anti-Iba-1 (1:500, Abcam Cat# ab5076, RRID: 
AB_2224402) in 1X PBS, overnight at 4ºC in a humid chamber. For secondary detection, 
sections were incubated for 2 h at room temperature in a dark chamber with fluorescent-dye 
conjugated secondary antibodies (Abcam Cat# ab150129, RRID: AB_2687506). Slides were 
mounted with fluorescence media with DAPI (Vectashield, Vector Laboratories, USA) and 
images were acquired in a fluorescence microscope (BX-50 Olympus, USA), through an 
incorporated digital camera (3CCD, Sony, USA) and processed with Image J software (NIH, 
Bethesda, MD, USA). The number of Iba-1 positive cells was counted in an area of 500 x 500 
pixels (12 images per treatment).  
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2.7 Reverse Transcription and quantitative real time polymerase chain reaction (RT-qPCR) 
assays 
Reverse transcription was performed using MMLV reverse transcriptase (Life Technologies, 
Argentina) as previously described
41
. Amplifications by qPCR were carried out in a Rotor-
Gene 6000 Corbett Life Science Real Time Thermal Cycler (Corbett Research, Sidney, NSW, 
Australia) and quantified with the Rotor Gene 6000 Series Software (version 1.7 Build 40, 
Hilden, Germany). Primer oligonucleotide sequences used in this study are listed in 
Supplementary Table 1. Gene expression levels were normalized to Actb (β-Actin) as an 
internal control, using the ΔΔCt relative quantification method42. 
 
2.8 Immunoblot analysis 
Pituitary homogenates were resolved by SDS-PAGE and transferred to polyvinylidinefluoride 
membranes in a Trans-Blot Semi-Dry system (Bio-Rad Laboratories Inc., USA). PVDF 
membranes were blocked in 20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 0.1% Tween 20, and 
5% nonfat milk for 60 min at room temperature and then incubated overnight with the 
indicated dilution of the following antisera at 4ºC: 1:2500 mouse ACTH mAb (Santa Cruz 
Biotechnology Cat# sc-52980, RRID:AB_831670), 1:2000 rabbit Nitro-tyrosine pAb (Sigma-
Aldrich Cat# N0409, RRID:AB_260745), 1:1000 rabbit heme oxygenase-1 (HO-1) pAb 
(Enzo Life Sciences Cat# ADI-SPA-896, RRID:AB_10614948), 1:1000 rabbit F4/80 pAb 
(Santa Cruz Biotechnology Cat# sc-25830, RRID:AB_2246477) and 1:1000 mouse actin 
mAb (Santa Cruz Biotechnology Cat# sc-47778 HRP, RRID:AB_2714189). Membranes were 
then incubated with a 1:20000 dilution of either Goat anti-Rabbit IgG (Bio-Rad / AbD 
Serotec Cat
# 
170-6515, RRID:AB_11125142) or Horse anti-Mouse IgG horseradish 
peroxidase conjugate (Cell Signaling Technology Cat# 7076, RRID:AB_330924) as 
described elsewhere
43
. Chemiluminescence was detected with the Image Quant Imaging 
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System (GE Healthcare, PA, USA) and quantification was performed using Image J software 
(NIH, Bethesda, MD, USA).  
 
2.9 Cell Lines and Culture Conditions 
The mouse ACTH-secreting pituitary adenoma cell line, AtT-20/D16v-F2 (named AtT-20 
hereafter)
44
 was obtained from the American Type Culture Collection (ATCC, Manassas, 
USA). AtT-20 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM-
Invitrogen, Argentina) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 
100 U/ml penicillin, 100 μg/ml streptomycin at 37°C and 5% CO2. All treatments were 
performed in serum-free DMEM.  
 
Mouse macrophage-like cells, J774.1, were kindly provided by Dr. Alejandra Goldman 
(Universidad Nacional de San Martín, Argentina) and maintained in DMEM medium 
supplemented with 100 U/mL of penicillin, 100 μg/mL of streptomycin, 100 U/ml 
amphotericin B and 10% FBS at 37 °C and 5% CO2. J774.1 cells were incubated in the 
presence or absence of 100 ng/ml LPS (Escherichia coli endotoxin, serotype O111:B4) and 
7.5 mM D-glucose and 50 nM melatonin. After 6 h, the cells were washed three times with 
PBS, and the medium was replaced with complete culture medium. After culturing the cells 
for another 24 h the conditioned media were collected, centrifuged at 1950 g for 20 min, and 
then filtered through 0.22-μm-pore filters (Millipore, Billerica, MA, USA) to remove cells 
and debris.  
 
Cell viability, assessed by the Trypan-blue exclusion method, was calculated as % ratio of 
viable cells (unstained) to total cells. None of the treatments described in this study affected 
cell viability assessed by Trypan-blue exclusion method.  
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2.10 Transfections and reporter assays 
AtT-20 cells were seeded in 96-well plates (10
4
cells per well) and transfected using 
Lipofectamine 2000
®
 (Invitrogen Argentina, Argentina), pPOMC-pGL3 and pGL3-NFκB-
LUC (pκB-LUC) (0.18 μg/well, Addgene, Cambridge, MA, USA) and pCMV-β-gal (0.02 
μg/well) following manufacturer’s instructions. Luciferase activity was determined using the 
Steady-Glo Luciferase Assay System (Promega Corporation, Madison, WI, USA). Values 
were normalized to β-galactosidase activity. pPOMC-pGL3 was provided by Dr. Domenico 
Accili (Addgene plasmid #17553)
45
. pκB-LUC, containing five NFκB response elements, was 
kindly provided by Dr. Omar Coso (FCEyN, UBA,  Argentina)
46
. 
 
2.11 Statistical Analysis 
Data is presented as mean ± standard error of the mean. Differences between groups were 
analyzed by two-tailed unpaired Student’s t test or by one-way ANOVA, as appropriate. 
When the ANOVA yielded significant differences (p<0.05), post hoc comparisons (Tukey’s 
tests) were made to determine the statistical difference between groups. All calculations were 
performed using Prism 7 for Mac OSX Version 7.0a (GraphPad Software, CA, USA).  
 
3. Results 
3.1 Early functional changes in pituitary glands from SRD-treated animals 
Figure 1 shows significantly higher systemic levels of ACTH and corticosterone after a short 
treatment with SRD (Figure 1A and 1B, respectively) compared to controls. Accordingly, 
increased levels of Pomc mRNA (Figure 1C) and ACTH protein (Figure 1D) were detected in 
pituitary tissues from SRD-treated rats. Interestingly, after three weeks of SRD a significant 
decrease in nocturnal serum melatonin levels was detected (Control: 160.7  18.2 pg/ml n=4, 
SRD: 98.9  8.2 pg/ml n=6 p=0.0081). 
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As shown in Figure 2, three weeks of treatment with SRD induced an increase in pituitary 
TBARS levels (Figure 2A), catalase activity (Figure 2B), hemoxygenase-1 (HO-1) expression 
levels (Figure 2C) and nitrotyrosine-modified protein immunoreactivity (data not shown). In 
addition, an immunohistochemical analysis indicated a significantly higher number of Iba-1 
(+) cells in the pituitary glands obtained from SRD-treated rats (Figure 2D). An increase in 
the protein levels of F4/80, a macrophage marker (Figure 2E), in mRNA levels of Il1b and 
the inflammasome components Asc and Nalp3 (Figure 2F) and in the mRNA levels of Tnfa 
(data not shown) were also observed in this group.  
 
3.2 Preventive effects of melatonin treatment on SRD-induced pituitary dysfunction 
Table 1 shows that rats fed a SRD for three weeks exhibited significantly higher fasting 
serum levels of glucose, non-esterified fatty acids (NEFA), and TAG, without significant 
differences in body weights compared to the corresponding controls. The administration of 
melatonin did not affect these parameters either in control or in SRD-treated rats.  
 
Melatonin treatment prevented the SRD-dependent increase in pituitary lipid peroxides 
(Figure 2A), catalase activity (Figure 2B) and HO-1 (Figure 2C) protein levels. In addition, 
melatonin also blocked the increase in Iba-1-immunoreactivity (Figure 2D) and F4/80-protein 
levels (Figure 2E) in pituitary glands from SRD-treated rats. The SRD-dependent increase in 
the pituitary expression of Il1b and the inflammasome components Asc, Nalp3, was also 
prevented by melatonin (Figure 2F). In addition, melatonin treatment suppressed the SRD-
induced increase in ACTH protein levels (Figure 3A) as well as in systemic levels of ACTH 
(Figure 3B) and corticosterone (Figure 3C).  
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3.3 Effects of melatonin on the immune-endocrine interactions that lead to increased 
POMC/ACTH expression in AtT-20 cells. 
In order to test whether inflammatory mediators could contribute to the induction of Pomc, 
we treated corticotroph cells (AtT-20) with conditioned media (CM) obtained from mouse 
J774 macrophages stimulated with LPS (100 ng/ml) and/or moderately high glucose levels 
(D-Glu, 7.5 mM) in the presence or absence of melatonin (50 nM) (Figure 4A). This 
treatment resulted in a seven-fold increase in Il1b levels in J774 cells (data not shown). As 
indicated in Figure 4 B and C, when AtT-20 cells were incubated with CM obtained from 
macrophages stimulated with LPS+GLU, luciferase activity of the reporter plasmids pκB-Luc 
(Figure 4B) and POMC-pGL3 (Figure 4C) was significantly increased. Similar results were 
obtained by analyzing ACTH expression levels by immunoblot (Figure 4D). These effects 
were not observed when CM was obtained from macrophages stimulated with LPS+Glu in 
the presence of melatonin (Figures 4B-D).  
 
Discussion 
Our results indicate that a short-term SRD administration (three weeks) induced significant 
changes in the activity of the HPA axis including an increase in systemic ACTH and 
corticosterone concentrations that correlated with elevated levels of Pomc and ACTH at the 
pituitary level. In addition, the occurrence of oxidative stress and inflammation was detected 
in the adenohypophysis of these animals. Present results also indicate that a treatment with 
melatonin prevented the SRD-dependent induction of oxidative stress and inflammation in the 
adenohypophysis and normalized the activity of the HPA axis. Moreover, since SRD 
decreased serum melatonin levels, it is tempting to speculate that decreased endogenous 
melatonin levels could contribute to the pituitary dysfunction described herein. 
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Previous studies support an important role of melatonin as a physiological regulator of the 
HPA axis in animals. In this line, early reports have shown an increase in corticosterone 
levels in young pinealectomized animals, that is lost in old rats
47
. The involvement of an age-
related decrease in melatonin production
48
 in the higher corticosterone levels in old rats was 
suggested. In agreement, studies by Konakchieva et al.
49,50
 demonstrated that melatonin 
administration for 5 days significantly reduces corticosterone secretion, attenuates the 
adrenocortical response to stress and increases HPA axis sensitivity to glucocorticoid 
suppression.  Melatonin treatment decreases corticosterone levels in a mice model of chronic 
mild stress
51
 and CRH, ACTH, corticosterone , and cytokine levels) in LPS-treated diabetic 
(STZ) rats
52
. More recently, Zhou et al. have shown that melatonin or MT1/MT2 agonists 
(piromelatin or Neu-P11) decrease urinary corticosterone levels in high-fat fed rats under 
chronic stress or in diabetic rats
53,54
.  
 
Several reports have demonstrated that increased nutrient availability generates oxidative 
stress as a result of ROS/RNS production from mitochondria and other sources that surpasses 
the antioxidant capacity of the tissue
55-57
. Since SRD-treatment induced higher systemic 
levels of glucose, TAG and NEFA, it seems likely that an increased supply of nutrients could 
lead to the generation of oxidative stress, leading in turn to a pituitary dysfunction. In this 
regard, here we show an increase in lipid peroxidation along with the induction of catalase, 
and HO-1 in the pituitary gland from SRD-treated rats.  
 
Oxidative stress has been associated with the generation of a low grade inflammatory state in 
the liver, the adipose tissue, and other tissues (for review see
58,59
). In particular, an increase in 
the number of adipose tissue macrophages has been linked to the expansion and inflammation 
of the adipose tissue, and to the occurrence of IR and type 2 diabetes (for review see
60
). 
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Activation of tissue macrophages in IR animals is not restricted to adipose tissue, as it has 
been also demonstrated in liver, skeletal muscle, and pancreatic islets
60
. In agreement, our 
results showed that administration of a SRD for three weeks provoked an increase in the 
number of pituitary macrophages, the induction of inflammasome-associated proteins, and the 
expression levels of IL1-β in the pituitary gland. Although both M1 and M2-like 
macrophages have been detected in the anterior pituitary gland from control rats
61
, the 
increase in Il1b production in the adenohypophysis of SRD-treated rats suggests an imbalance 
in favor of pro-inflammatory macrophages.  
 
Since both oxidative and inflammatory mechanisms could be involved in the development of 
the diet-induced pituitary dysfunction, we next wonder if a treatment with melatonin, a well-
known antioxidant and anti-inflammatory molecule, could prevent the early dysregulation of 
the HPA axis induced by the administration of SRD
32,35
. Several reports have indicated that 
melatonin administration could decrease glycemia, as well as serum cholesterol and TAG 
levels
62-64
. In our study, melatonin administered as a subcutaneous pellet throughout the 
duration of the experimental period, following a protocol previously validated
37,65,66
, did not 
affect these biochemical parameters. This discrepancy could be due to differences in 
administration routes, dosages and treatment duration. Nevertheless, melatonin treatment was 
effective in preventing the generation of oxidative stress in the adenohypophysis of SRD-
treated rats (as shown by a decrease in lipoperoxide levels). As the induction of the 
antioxidant defense system could be triggered by ROS, this effect of melatonin could also 
account for the significant decrease in the levels of antioxidant enzymes.  
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Macrophages can induce non-infectious inflammatory reactions through the recognition of 
danger-associated molecular patterns (DAMPs) released upon cellular injury. Binding of 
DAMPs to pattern-recognition receptors activates different intracellular pathways. Among 
them, activation of the NLP3-inflammasome pathway leads to the production of IL-1 and 
IL-18
67-69
. Several studies have demonstrated the association between inflammasome 
activation and obesity-induced inflammation, insulin resistance, type 2 diabetes
70-72
, acute and 
chronic liver diseases
73,74
, and diabetic nephropathies
75
. Our results on the activation of the 
NLP3-inflammasome are, to our knowledge, the first report on the activation of this pathway 
in the pituitary gland of rats fed a SRD. Melatonin treatment not only prevented the increase 
in the number of macrophages but also blocked the induction of IL-1β and components of the 
NLP3-inflammasome in the adenohypophysis. In agreement with our results, prevention of 
NLP3-inflammasome activation by melatonin has been demonstrated in inflammatory 
diseases and sepsis
35,76,77
. In harmony with these results, melatonin has been shown to favor 
the anti-inflammatory M2 phenotype over M1 in liver Kupffer cells, peritoneal macrophages, 
and splenocytes from stressed mice
78
.  
 
Our hypothesis on the involvement of oxidative/inflammatory effects in the pituitary 
dysfunction seems to be consistent with the melatonin-induced prevention of the increase in 
pituitary and systemic levels of ACTH and corticosterone in SRD-treated rats.  
 
DAMPs generated within the pituitary gland as a consequence of the deleterious effects of 
ROS/RNS on cellular components, could attract and stimulate macrophages to produce 
cytokines that in turn impact on POMC production by corticotrophs. We thus speculate that a 
cross-talk could be established within the pituitary gland between activated tissue 
macrophages and corticotrophs. This hypothesis was supported by the results of experiments 
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in which AtT-20 cells were incubated with conditioned media obtained from macrophages 
activated with LPS and mild supraphysiological glucose concentrations. In these experimental 
setting we observed the stimulation of the NFB pathway and the induction of POMC 
expression in AtT-20 cells. Similar results were obtained when these cells were incubated in 
the presence of IL-1β and other cytokines20,24. Since melatonin treatment of macrophages 
prevented the stimulatory effect of conditioned media on POMC expression in AtT-20 
corticotrophs, we suggest that by inhibiting the production of IL-1β (by blocking 
inflammasome activation)
79,80
 or other cytokines by local macrophages, as previously 
demonstrated in RAW264.7 cells
81
, melatonin could prevent the simulation of POMC/ACTH 
by pituitary corticotrophs in SRD-treated rats. An additional effect of melatonin in preventing 
ROS-dependent negative feed-back regulation of glucocorticoids on corticotroph POMC 
production as described by Asaba et al.
82
 could not be discarded.  
 
As previously indicated, melatonin effects on cellular physiology involves a variety of 
mechanisms. Some of them implicate its binding to specific receptors followed by activation 
of signal transduction pathways. However, melatonin exerts many of its antioxidant and anti-
inflammatory effects by receptor-independent effects
83,84
. In favor of this mechanism, 
Johnston et al.
85
 demonstrated the expression of melatonin type 1 receptors (MT1) receptors 
in the rat fetal pituitary pars distalis which declines after birth, while other studies 
demonstrated a weak staining of MT1 receptors in this area (but a strong one in pars 
tuberalis)
86
, while the presence of melatonin receptors has been demonstrated in brain areas 
that could modulate the activity of the HPA axis
86,87
. Nonetheless, Jusczak et al.
88
 showed 
that intracerebroventricular infusion of melatonin resulted in a significant decrease in rat 
plasma ACTH levels that could not be blocked by receptor antagonists (luzindole or 4-
phenyl-2-propionamidotetralin). Notwithstanding, Fischer et al. demonstrated that an acute 
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treatment with melatonin (2.5 h) in mice stimulated POMC expression in the pituitary pars 
distalis, an effect that was not observed in MT1
-/- 
mice
89
. Altogether, melatonin could affect 
HPA axis activity by exerting direct effects on pituitary pars distalis (receptor-independent) 
by interacting with MT1/MT2 receptors, by other mechanisms (e.g., free radical scavenger, 
interaction with orphan nuclear receptors and molecules, as calmodulin) or by a combination 
of some or all the above. The complexity of the processes involved makes it difficult to 
determine the precise contribution of each mechanism to the effect of melatonin on the HPA 
axis activity. This issue will be explored in future studies. 
 
In summary, present results suggest that the diet-induced metabolic burden imposed on the 
anterior pituitary gland generates oxidative stress and inflammation. As a result of the 
deleterious effects associated with the production of ROS/RNS, metabolites or damaged 
cellular components released to the extracellular medium signal the recruitment of circulating 
monocytes and activate tissue macrophages to produce cytokines. These effectors, in turn, 
stimulate the synthesis of POMC and ACTH by pituitary corticotrophs. By preventing the 
diet-induced HPA axis dysfunction, melatonin appears to be a suitable therapeutic option to 
attenuate the metabolic effects of glucocorticoid overproduction.  
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Table 1: Melatonin treatment does not affect biometric or biochemical parameters in 
control and SRD-treated rats.  
 n 
Serum glucose 
(mg/dl) 
Serum TAG 
(mg/dl) 
Serum NEFA 
(mM) 
Body weight 
(g) 
CONTROL 12 91.21.6 75.54.4 0.680.04 330.58.8 
SRD 12   113.43.4*** 101.08.8*     1.150.07*** 356.820.7 
MEL 12 85.45.0 82.44.1 0.750.04 321.025.0 
SRD+MEL 12 107.34.2* 103.48.1*    0.980.05*** 335.520.4 
 
Serum levels of glucose, triacylglycerides (TAG) and non-esterified fatty acids (NEFA) were 
determined in blood samples obtained from rats of each experimental group after three weeks 
of treatment. Average body weight of rats from each group was determined at the end of the 
experimental period. Data from three independent experiments performed in quadruplicate 
are shown as mean ± SEM; 
*
p<0.05, 
**
p<0.01, 
***
p<0,001 vs. Control by ANOVA followed 
by Tukey’s post hoc test. 
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Figure Legends 
 
Figure 1: HPA axis activity is increased in rats fed a sucrose rich diet (SRD) for three 
weeks. Control and SRD-treated rats were analyzed for plasma ACTH (A) and serum 
corticosterone (B) by a chemiluminiscent immunoassay and RIA respectively. Pituitary 
relative Pomc mRNA levels were determined by RT-qPCR. Values are expressed as mean ± 
SEM, n=10 (A, B) and n=5 (C) animals per group; 
*
p<0.05 and 
***
p<0.001, by unpaired 
Student’s t test. (C) A representative western blot for pituitary ACTH protein levels is shown 
in (D).  
 
Figure 2: Oxidative stress and inflammatory parameters in the adenohypophysis were 
normalized by melatonin treatment. A) Lipoperoxide levels, B) catalase activity. Data is 
shown as mean ± SEM, n=5 animals per group; 
*
p<0.05, 
**
p<0.01, 
***
p<0.001 by ANOVA 
followed by Tukey’s post hoc test. C) Hemeoxygenase-1 expression levels. A representative 
western blot of 3 independent experiments is shown. D) Immunohistochemical detection of 
Iba-1 positive cells (green) and the corresponding densitometric analysis on the side. Nuclei 
were stained with DAPI (blue). Scale bar= 75 µm. Data is shown as mean ± SEM of #Iba1 
positive cells in 10 fields/animal. 
***p<0.001 by ANOVA followed by Tukey’s post hoc test. 
E) A representative western blot of three independent experiments showing F4/80 protein 
levels. F) mRNA relative levels of IL1b and inflammasome components Casp1, Asc, Nalp3, 
by RT-qPCR. Data is shown as mean ± SEM, n=4 animals per group; 
*
p<0.05, 
***
p<0.001 vs. 
Control, and 
#
p<0.05, 
###
p<0.001 vs. SRD by ANOVA followed by Tukey’s post hoc test. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure 3: Melatonin treatment prevents the hyperactivation of the HPA axis induced after 
three weeks of SRD. A) A representative western blot of pituitary ACTH expression levels is 
shown below the densitometric analysis of blots from three independent experiments. Data is 
shown as mean ± SEM; 
***p<0.001 by ANOVA followed by Tukey’s post hoc test. B) plasma 
ACTH concentration was determined by a chemiluminiscent immunoassay, and C) serum 
corticosterone levels by RIA. Data is shown as mean ± SEM, n=10 animals per group; 
***p<0.001 by ANOVA followed by Tukey’s post hoc test.  
 
Figure 4: Melatonin prevents stimulation of POMC/ACTH expression in corticotroph cells 
by conditioned media from activated macrophages. A) Murine J774 macrophage cells were 
incubated with or without 100 ng/ml LPS, 7.5 mM D-glucose (D-Glu) and 50 nM melatonin 
(MEL) for 6 hours. Cells were washed, media was replaced and incubations proceeded for 
another 18 h. Conditioned media (CM) was collected and stored at -80ºC. AtT-20 cells were 
transfected with pPOMC-pGL3 (B) or pκB-LUC (C) and incubated for 24 h in the presence 
of CM obtained as shown above. D) AtT-20 cells were incubated as before and ACTH protein 
levels were analyzed by western blot. Data is shown as mean ± SEM, n=4, 
**
p<0.01, 
***p<0.001 by ANOVA followed by Tukey’s post hoc test.  
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